

TABLE 1. Baseline patient characteristics

	All patients	Evolocumab	Alirocumab
Number	37	19	18
Age, years	54 (50-71)	52 (49-65)	55 (50-76)
	n (%)	n (%)	n (%)
Female	16 (43)	10 (53)	6 (33)
Current smoking	6 (16)	3 (18)	3 (15)
Coronary artery disease	22 (60)	9 (47)	13 (72)
Cerebrovascular disease	6 (16)	2 (11)	4 (22)
Hypertension	17 (46)	7 (37)	10 (56)
Diabetes	10 (27)	4 (21)	6 (33)
Carotid artery disease	9 (24)	6 (32)	3 (17)
Chronic kidney disease	4 (11)	1 (5)	3 (17)
FH			
HoFH	3 (8)	2 (11)	1 (6)
HeFH	24 (65)	8 (42)	16 (89)
LEAD	3 (8)	1 (9)	2 (11)
No statin	2 (5)	2 (11)	0
Rosuvastatin	29 (78)	15 (79)	14 (78)
Atorvastatin	4 (11)	1 (5)	3 (16)
Pitavastatin	2 (5)	1 (5)	1 (5)
Ezetimibe	35 (95)	17 (90)	18 (100)
Fenofibrate	3 (8)	2 (11)	1 (6)
Omega 3 fatty acids	1 (3)	0	1 (6)
Colesevelam	6 (16)	5 (26)	1 (6)
Intolerance to statins			
Partial intolerance	5 (14)	3 (16)	2 (11)
Total intolerance	3 (8)	3 (16)	0

Abbreviations: FH: familial hypercholesterolemia, LEAD: lower extremities arterial disease